secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-08-11T20:00:59+00:00
Accession:  0001140361-26-032231
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Apogee stockholders approve AbbVie merger; advisory comp proposal fails
-----------------------------------------------------------------------

- Merger proposal approved: 46,508,107 for, 3,885 against, 14,261 abstentions, satisfying a closing condition.
- Non-binding compensation proposal failed: 19,323,605 for vs 27,123,259 against; not a condition to close.
- All seven directors (Henderson, McKenna, Bollinger, Fox, Jones, Kiselak, Shah) to resign effective at merger close.
- Special meeting quorum: 46,526,253 shares (74.87% of 62,140,183 outstanding) present.
- Apogee to become indirect wholly-owned subsidiary of AbbVie upon merger completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000114036126032231/0001140361-26-032231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000114036126032231/ef20079870_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-032231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer